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bcl-2, the prototypic cellular antiapoptotic gene, decreases Sindbis virus replication and Sindbis virus-
induced apoptosis in mouse brains, resulting in protection against lethal encephalitis. To investigate potential
mechanisms by which Bcl-2 protects against central nervous system Sindbis virus infection, we performed a
yeast two-hybrid screen to identify Bcl-2-interacting gene products in an adult mouse brain library. We iden-
tified a novel 60-kDa coiled-coil protein, Beclin, which we confirmed interacts with Bcl-2 in mammalian cells,
using fluorescence resonance energy transfer microscopy. To examine the role of Beclin in Sindbis virus
pathogenesis, we constructed recombinant Sindbis virus chimeras that express full-length human Beclin (SIN/
beclin), Beclin lacking the putative Bcl-2-binding domain (SIN/beclinDBcl-2BD), or Beclin containing a pre-
mature stop codon near the 5* terminus (SIN/beclinstop). The survival of mice infected with SIN/beclin was
significantly higher (71%) than the survival of mice infected with SIN/beclinDBcl-2BD (9%) or SIN/beclinstop
(7%) (P < 0.001). The brains of mice infected with SIN/beclin had fewer Sindbis virus RNA-positive cells, fewer
apoptotic cells, and lower viral titers than the brains of mice infected with SIN/beclinDBcl-2BD or SIN/
beclinstop. These findings demonstrate that Beclin is a novel Bcl-2-interacting cellular protein that may play
a role in antiviral host defense.
The cellular antiapoptotic gene bcl-2 represents a novel class
of antiviral host defense molecules which function both by
restricting viral replication and by preventing virus-induced
cell death. Bcl-2 blocks apoptosis in vitro induced by several
different RNA viruses, including Sindbis virus (18, 41), influ-
enza virus (13, 26), reovirus (31), Semliki Forest virus (34),
LaCrosse virus (29), and Japanese B encephalitis virus (21).
Previously, we have shown that Bcl-2 overexpression in virally
infected neurons in vivo also protects mice against fatal en-
cephalitis caused by the prototypic alphavirus, Sindbis virus
(17). The protective effects of Bcl-2 against fatal Sindbis virus
encephalitis were associated with a reduction both in neuronal
apoptotic death and in central nervous system (CNS) viral
replication. A similar antiviral effect of Bcl-2 overexpression
has been observed during Sindbis virus infection in cultured
AT3 cells (41) as well as during influenza virus infection of
MDCK cells (26), Japanese B encephalitis virus infection of
N18 cells (21), and Semliki Forest virus infection of AT3 cells
(34). Although the role of endogenous Bcl-2 in antiviral de-
fense has yet to be evaluated, these studies support the hy-
pothesis that Bcl-2 may be important in protecting cells against
viral infections.
Most previous studies examining the effects of Bcl-2 on viral
infections have been with neurotropic RNA viruses (e.g., Sind-
bis virus, reovirus, Semliki Forest virus, LaCrosse virus, and
Japanese B virus) (18, 21, 29, 31, 34, 41). Although Bcl-2 may
affect viral replication and virus-induced apoptosis with non-
neurotropic viruses (e.g., influenza virus) (13, 26), host mech-
anisms to inhibit apoptosis may be of particular importance
during viral infections of vital, nonrenewable cell populations
such as neurons. In such instances, virus-induced apoptotic
death of neurons may result in irreversible CNS pathology and
death of the host organism (1, 17, 19, 25). Therefore, while
apoptosis in other cell types may be an adaptive host defense
strategy that reduces total viral burden for the organism (re-
viewed in references 11, 16, 36, and 39), unique strategies may
have evolved to permit control of CNS viral replication without
inducing apoptotic death of infected neurons. It is thus possi-
ble that cellular genes that play a role in preventing apoptosis
during normal neuronal development (e.g., bcl-2 and bcl-xL)
(reviewed in reference 23) may also be important in regulating
CNS viral replication and in defending against apoptosis in-
duced by neurotropic viruses.
To further understand how the cellular gene bcl-2 exerts
antiapoptotic and antiviral effects during CNS viral infection,
we performed a yeast two-hybrid screen to identify Bcl-2-in-
teracting gene products in adult mouse brain. In this study, we
describe the identification of a novel Bcl-2-interacting gene
product, which we named Beclin because of its predicted
coiled-coil structure (hence, the “-in” suffix) and its interaction
with Bcl-2 (Becl). Like Bcl-2 overexpression, Beclin overex-
pression in neurons in vivo can inhibit Sindbis virus replication,
reduce CNS apoptosis, and provide protection against fatal
Sindbis virus infection. A Beclin construct lacking the putative
Bcl-2-binding domain provides no protection and has no anti-
viral activity. Thus, our findings identify a novel protein, Bec-
lin, which may play a role in host defense against Sindbis virus
infection. In addition, they suggest that interactions with Bcl-
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2-like proteins may be important for the protective activity of
Beclin.
MATERIALS AND METHODS
Plasmids. To construct vectors for transient expression in mammalian cells,
the open reading frame of human bcl-2, flag epitope-tagged human beclin, and
flag epitope-tagged beclin deleted of nucleotides 238 to 453 were cloned into
pSG5 (Stratagene). To construct viral cDNA clones, the previously described
neurovirulent double subgenomic Sindbis virus vector dsTE12 was used (17).
Full-length flag epitope-tagged human beclin, human beclin containing a stop
codon inserted at nucleotide position 270, human beclin containing an in-frame
deletion of nucleotides 238 to 453, human bcl-2, and human bcl-2 containing a
stop codon at nucleotide position 118 were cloned into the BstEII site of dsTE12
to generate plasmids SIN/beclin, SIN/beclinstop, SIN/beclinDbcl-2BD, SIN/bcl-2,
and SIN/bcl-2stop, respectively. To construct vectors for yeast two-hybrid studies,
the sequences encoding amino acids (aa) 1 to 218 of human bcl-2, 1 to 212 of
bcl-xL, 1 to 149 of bcl-xS, and 1 to 171 of bax were cloned into pGBT9 in frame
with the GAL4 DNA-binding domain. To avoid difficulties with targeting of
proteins to the nucleus, the sequences encoding C-terminal transmembrane
domains of bcl-2 family members were omitted. Control pGBT9 plasmids con-
taining lamin (pLAM59) and p53 (pVA3) inserts were obtained from Clontech.
Yeast two-hybrid screen. Saccharomyces cerevisiae SFY526 cells were cotrans-
formed with pGBT9/bcl-2 and 106 cDNA molecules from an adult mouse brain
library fused to a GAL4 activation domain vector (pGAD10; Clontech), plated
onto SD medium lacking tryptophan and leucine, incubated at 30°C for 4 days,
and then screened for LacZ activity by a colony lift filter assay. Putative inter-
acting clones were isolated by manipulation in leuB Escherichia coli, and further
tested against pGBT9 and control plasmids. A positive b-galactosidase reaction
between pGBT9/bcl-2 and clone F1 was obtained within 10 to 15 min. For
analysis of interactions between Beclin and Bcl-2 family members, pGBT9 plas-
mids containing bcl-2 family members were cotransformed with fragments of
human beclin (1 to 450, 262 to 450, and 1 to 708) fused to the GAL4 activation
domain in pGAD424, and transformants were screened for LacZ activity.
Sequencing and analysis of human beclin. The partial nucleotide sequence of
mouse beclin obtained from sequencing clone F1 was aligned with an overlapping
clone GT197 isolated from human breast (32). Primers immediately upstream
and downstream of the predicted open reading frame were used to amplify the
coding sequence of human beclin from a normalized human infant brain cDNA
library (37). The resulting PCR products from several independent reactions
were cloned into pCRII and sequenced in both directions, using Sequenase (U.S.
Biochemical) as well as automated sequencing. The resulting nucleotide se-
quence and deduced amino acid sequences were used to scan various data banks
(GenBank, EMBL, SwissProt, and PIR) for homologous sequences, using the
BLAST algorithms (2). The amino acid sequence was also analyzed by the
PROSITE program to identify functional motifs and by the COILS program to
identify coiled-coil regions (22).
Northern blot analysis. Human and mouse multiple tissue blots (Clontech)
were hybridized with 32P randomly labeled human or mouse beclin probes (nu-
cleotides 1 to 485) as instructed by the manufacturer (Clontech). Equal loading
[2 mg of poly(A) RNA] was confirmed by hybridization to a b-actin probe.
Production of recombinant viruses. The viruses SIN/beclin, SIN/beclinstop,
SIN/beclinDBcl-2BD, SIN/bcl-2, and SIN/bcl-2stop were generated from viral
cDNA clones as previously described (17). Briefly, 59-capped transcripts were
synthesized from cDNA clones linearized with PvuI (for beclin-containing vi-
ruses) or XhoI (for bcl-2-containing viruses), transcribed in vitro with SP6 DNA-
dependent RNA polymerase, and transfected into BHK cells by using Lipofectin
according to the manufacturer’s instructions. Twenty-four hours after transfec-
tion, virus particle-containing supernatants of transfected cell monolayers were
collected, frozen in aliquots at 70°C, and used for all subsequent experiments.
Titers of stock viruses were determined by plaque assay titration on BHK-21
cells.
Animal experiments. Ten-day-old litters of CD1 mice were inoculated intra-
cerebrally into the right cerebral hemisphere with 1,000 PFU of each recombi-
nant virus in 0.03 ml of Hanks’ balanced salt solution. For mortality experiments,
three to six separate litters were inoculated with each virus, and mortality was
determined by daily observation of the mice for 3 weeks after infection. For virus
titration and histopathology experiments, three to six mice per experimental
group were sacrificed at days 1, 2, and 4 after inoculation. The right cerebral
hemisphere was dissected and stored at 270°C, and freeze-thawed tissues were
used to prepare 10% homogenates in Hanks’ balanced salt solution for plaque
assay titration. The left cerebral hemisphere was fixed by immersion in 3%
paraformaldehyde.
Histopathology. Paraformaldehyde-fixed mouse brains were embedded in par-
affin, and a series of 4-mm parasagittal sections were cut at the level of the
olfactory bulb, extending caudally from the bulb to the cerebellum and medulla.
For each brain, sequential sections were stained by hematoxylin and eosin to
detect histopathology, in situ end labeling (ISEL) to detect apoptotic nuclei, in
situ hybridization to detect Sindbis virus RNA, and immunoperoxidase to detect
flag-Beclin protein expression. ISEL and in situ hybridization were performed by
methods identical to those described previously for SIN/bcl-2-infected mouse
brains (17). Immunoperoxidase staining to detect flag-Beclin protein expression
in SIN/beclin-, SIN/beclinDBcl-2BD-, and SIN/beclinstop-infected mouse brains
was performed by using the monoclonal anti-flag antibody M2 (5 mg/ml; VWR)
and the avidin-biotin peroxidase method (Vectastain ABC kit; Vector Labora-
tories) according to the manufacturer’s instructions.
The number of virus RNA-positive and ISEL-positive cells in each brain
section was quantitated with Image-ProPlus software. To calculate the number of
positive cells per brain section, nonoverlapping 0.25-mm2 microscopic fields
spanning the entire brain section were scanned with a 103 objective and constant
settings for brightness, contrast, and threshold values for positive events. The
number of positive events (i.e., RNA-positive cells or ISEL-positive cells) for
each brain section was determined by adding the sum of all individual fields
analyzed. The total number of positive events per brain section was divided by
the total area of the brain section to yield the average number of RNA-positive
or ISEL-positive cells per square millimeter of brain.
Sections of hippocampus and anterior cortex from an adult human were
stained with 843, a polyclonal antibody against a human Beclin peptide corre-
sponding to aa 1 to 15 (1:200 dilution; Eurogenetics, Seraing, Belgium), and
human Beclin was detected by the avidin-biotin peroxidase method.
Plasmid transfections. Plasmids pSG5/bcl-2 and pSG5/flag-beclin or pSG5/
bcl-2 and pSG5/flag-beclinDBcl-2BD (1 mg of each) were transiently transfected
into COS7 cells by using Superfect (Qiagen) according to the manufacturer’s
instructions.
Protein detection. For immunofluorescence studies, COS7 cells were fixed 24 h
after transfection with 100% ethanol. Expression of flag-Beclin and flag-mutant
BeclinDBcl-2BD mutant constructs was detected with an anti-flag epitope anti-
body (M2; 1:20; VWR) and fluorescein isothiocyanate (FITC)-conjugated horse
anti-mouse immunoglobulin G. Bcl-2 expression was detected with a polyclonal
rabbit anti-Bcl-2 antibody (1:100; Pharmingen) and rhodamine-conjugated goat
anti-rabbit antibody. SERCA (endoplasmic reticulum Ca21 ATPase) was de-
tected with an anti-SERCA antibody (1:500; Research Design, Inc.). Western
blot analysis to detect flag-Beclin expression in BHK cells infected with SIN/
beclin, SIN/beclinstop, and SIN/beclinDBcl-2BD was performed with either an-
tibody M2 (20 mg/ml) or anti-human Beclin peptide antibody 843 (1:200) and
enhanced chemiluminescence detection as instructed by the manufacturer (Am-
ersham).
FRET. Fluorescence resonance energy transfer (FRET) microscopy was per-
formed as previously described on COS7 cells cotransfected with bcl-2 and beclin
expression vectors (9). The donor (FITC) filter set had the following parameters:
excitation (ex) 5 450 to 490 nm; dichroic mirror (dm) 5 510 nm; emission (em)
5 590 long pass. The acceptor (rhodamine) filter set had the following param-
eters: ex 5 546 nm; dm 5 580 nm, em 5 590 long pass. Images obtained with
these two filter sets were used to directly quantify the intensities of each fluoro-
phore. The signal recorded from the FRET filter set (ex 5 450 to 490 nm; dm 5
580 nm; em 5 590 nm long pass) is from energy that has transferred from FITC
to rhodamine molecules. A mapping program described previously (9) was used
to map fluorescent cells and to quantify the intensity within each cell. Quanti-
tative analysis of these mapped images required solving three equations, one for
each filter set, which accounted for the excitation and detection of both labels in
all three filter sets as well as the concentrations of the donor and acceptor
molecules and the probability of transfer. The measured quantities are expressed
as follows, in which the first letter (uppercase) indicates the filter set (A, accep-
tor; F, FRET; D, donor) and the second letter (lowercase) indicates the labels
present (a, acceptor alone; f, acceptor and donor; d, donor alone). A solution of
the equation is E 5 1/[aconc(RK 1 1)], where aconc 5 (AdFf 2 FdAf)/[(AdFa/
Aa) 2 Fd]; R 5 (DaFf/Fa 2 Df)/[aconc ((Fa/Aa) 2 FdDa/DdAa) 2 F 5 FdDf/
Dd]; and K is proportional to the product of the ratio of the quantum yield of the
two labels and the ratio of the absolute detection efficiencies of the two labels.
Nucleotide sequence accession numbers. The GenBank accession numbers for
human and mouse beclin are AF077301 and AF077302, respectively.
RESULTS
Identification of beclin, a novel gene on chromosome 17q21.
Previously, we demonstrated that Bcl-2 inhibits Sindbis virus
replication and prevents Sindbis virus-induced apoptosis in
mouse neurons (17). To further understand the mechanisms by
which Bcl-2 protects against Sindbis virus infection in neurons,
we performed a yeast two-hybrid screen of an adult mouse
brain library for complementary DNAs encoding proteins that
bind to the cell death inhibitor Bcl-2. We constructed a bait
plasmid (pGBT9/bcl-2) by fusing human bcl-2 (lacking the C-
terminal signal-anchor sequence to ensure translocation to the
nucleus) to the GAL4 DNA-binding domain, which was co-
transformed with an oligo(dT) and random hexamer-primed
adult mouse brain cDNA fusion library in a GAL4 activation
domain vector, pGAD10. Of 1 million transformants, one
positive colony was identified by the 5-bromo-4-chloro-3-in-
dolyl-b-D-galactopyranoside (X-Gal) filter assay. Sequencing
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analysis of the cDNA plasmid rescued from this colony (F1)
revealed a termination codon 42 bp downstream from the
GAL4 activation domain, several predicted short open reading
frames between nucleotides 124 and 1843 and a longer pre-
dicted open reading frame (with a good Kozak consensus se-
quence and multiple stop codons upstream) spanning from
nucleotide 1855 to the 39 end of the insert. Thus, either the
14-aa fusion protein was interacting with Bcl-2 or one of the
downstream open reading frames encoded a protein that con-
tains its own activation domain and interacts with Bcl-2. To
identify the Bcl-2-interacting region of F1, we fused nucleo-
tides 1 to 1854 and 1855 to 2500 to the GAL4 activation do-
main in pGAD424 and tested for interactions with Bcl-2. Nu-
cleotides 1855 to 2500, but not 1 to 1854, encoded a protein
that interacts with Bcl-2 fused to the GAL4 DNA-binding do-
main (Table 1) but not with control GAL4 DNA-binding do-
main plasmids containing p53, lamin (Table 1), or Sindbis virus
glycoproteins (data not shown).
A database search revealed that the nucleotide sequence of
F1 (1855 to 2500) overlapped with sequences of several clones
isolated from a normalized infant human brain cDNA library
in the Merck EST (epitope tag sequence) database as well as
clones from human breast (GT197) (32) and human fibroblast
(B32) cells (8). These clones contain only partial open reading
frames of a novel gene that encodes a protein with coiled coils.
As explained above, we assigned the name beclin to this gene
because of the interaction of its encoded protein with Bcl-2
and the predicted coiled-coil structure of its encoded protein.
Clones GT197 and B32 were both isolated in the generation of
transcription maps of the breast cancer susceptibility locus on
chromosome 17q21 and are mapped to a region located ap-
proximately 100 kb centromeric to the gene BRCA1. They lie
within a 400-kb minimal deletion unit mapped by Tangir et al.
in sporadic epithelial ovarian cancers (38).
We aligned the overlapping partial clones in GenBank with
our mouse beclin sequence to obtain a predicted sequence of
the full-length open reading frame of human beclin and iso-
lated human beclin from a normalized human infant brain
cDNA library (37). Human beclin is predicted to encode a
novel 450-aa, 60-kDa protein containing a coiled-coil region
with 25 to 28% homology with myosin-like proteins (Fig. 1). It
shares 93% identity at the nucleotide level and 98% identity at
the amino acid level with the mouse beclin sequence identified
in the yeast two-hybrid screen. Human Beclin is also homolo-
gous with the Caenorhabditis elegans T19E7.3 gene product
(GenBank accession no. U42843) and the S. cerevisiae gene
product Lph7p (GenBank accession no. U43503) (38 and 37%
identical over 145 and 137 residues, respectively), indicating a
high degree of evolutionary conservation. PROSITE analysis
of human Beclin identified several potential glycosylation,
phosphorylation, and myristoylation sites but no other func-
tional sequence motifs.
Ubiquitous expression of beclin mRNA in mouse and human
tissues. To examine the tissue-specific pattern of beclin expres-
sion, we hybridized mouse and human multiple-tissue North-
ern blots with a beclin-specific probe. RNA blot analysis re-
vealed that expression of beclin mRNA is widespread in both
mouse and human adult tissue (Fig. 2A). A beclin-specific
probe hybridized to a 2.2-kb transcript present at highest levels
in human skeletal muscle but at detectable levels in all tissues
examined. The size of this transcript is approximately the same
as that observed previously for clones GT197 and B32 (8, 32).
In some tissues, additional 1.7- and 1.4-kb transcripts were
observed, suggesting the presence of alternatively spliced tran-
scripts.
Beclin is expressed in human neurons. To examine whether
Beclin protein is expressed in neurons (the primary CNS target
cell type for Sindbis virus infection), we performed immuno-
peroxidase staining of adult human brain sections. We used
rabbit immune serum 843, generated against a human Beclin
peptide corresponding to aa 1 to 15. 843 reacts with a 61-kDa
protein in lysates prepared from BHK cells after infection with
a recombinant Sindbis virus containing a flag epitope-tagged
human beclin insert (SIN/beclin) (Fig. 3B). This protein mi-
grates identically to the major band detected with an anti-flag
epitope antibody in SIN/beclin-infected BHK cell lysates (Fig.
3A) and to in vitro translated flag-Beclin (data not shown).
Immunoperoxidase staining of human brain sections from the
hippocampus and frontal cortex revealed Beclin immunoreac-
tivity in many neurons throughout these regions as well as in
some glial cells. In neurons, Beclin demonstrated a granular,
punctate pattern of staining that was found almost exclusively
in the region of the perikaryon (Fig. 2B). Beclin immunoreac-
FIG. 1. Deduced amino acid sequence of human Beclin. The boxed area
represents the Bcl-2-binding domain of human Beclin (Table 1), and the under-
lined area corresponds to the region that is predicted to have a coiled-coil
conformation.
TABLE 1. Summary of yeast two-hybrid assay results
GAL4 activation
domain plasmidb
b-Galactosidase reaction with GAL4
binding domain constructa
Empty Bcl-2 Bcl-xL Bcl-xS Bax Lamin p53
Empty 2 2 2 1 2 2 2
F1
1–2563 2 1 1 ND 2 2 2
1–1855 2 2 2 ND 2 2 2
1856–2563 (Mus
Beclin 1–708)
2 1 1 ND 2 2 2
Human Beclin
1–708 2 1 1 ND 2 2 2
Beclin 1–450 2 1 1 ND 2 2 2
Beclin 1–258 2 2 2 ND 2 2 2
Beclin 262–450 2 1 1 ND 2 2 2
Beclin 451–708 2 2 2 ND 2 2 2
Beclin 1–1353 2 2 2 ND 2 2 2
a 1, positive reaction within 15 min; 2, lack of positive reaction at 24 h; ND,
not determined.
b Nucleotide positions of genes fused to the plasmid.
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tivity was also observed in the media of blood vessels, in the
ependymal cells, and in the choroid plexus. No staining was
observed in human brains stained with rabbit preimmune se-
rum 843 (data not shown).
Interaction of Beclin and Bcl-2. We performed additional
yeast two-hybrid studies to confirm that human beclin, like
mouse beclin, encodes a protein that interacts with human
Bcl-2 and to further define the Bcl-2-interacting region of
human Beclin (Table 1). We found that the region of human
Beclin that corresponds to the mouse gene product isolated in
the yeast two-hybrid screen (aa 1 to 236) also interacts with
Bcl-2. Further deletion mutation analysis revealed that aa 88 to
150 of Beclin were sufficient to mediate an interaction with
Bcl-2. Interestingly, the coding sequence for this region of
Beclin is deleted in some human infant brain cDNA clones in
the Merck EST database, suggesting that Beclin exists in at
least two forms, including one that contains a Bcl-2-binding
domain and one that lacks this domain. Full length-Beclin does
not interact with Bcl-2 in the yeast two-hybrid system. As noted
below, when expressed in transient transfection assays, flag-
tagged full-length human Beclin displays a punctate immuno-
reactivity pattern suggestive of association with intracellular
organelles and is associated with the insoluble fraction after
cell lysis. In contrast, a flag-tagged truncated Beclin (aa 1 to
236) (corresponding to the region isolated in the yeast two-
hybrid screen) displays a diffuse cytoplasmic staining pattern
and is soluble after cell lysis. These differences between full-
length and truncated Beclin are thought to account for differ-
ences in ability to translocate to yeast nuclei and interact with
Bcl-2 in the yeast two-hybrid assay.
To directly examine whether full-length human Beclin and
Bcl-2 interact in mammalian cells, we performed FRET studies
of COS7 cells cotransfected with Bcl-2 and flag epitope-tagged
Beclin. Beclin is predicted to be a coiled-coil protein that may
be associated with the cytoskeleton, and it partitions with the
insoluble fraction following cell lysis. For this technical reason,
biochemical analyses of in vivo interactions between Bcl-2 and
Beclin cannot be performed. FRET is a fluorescence technique
that can be used as a spectroscopic ruler to study and quantify
the interactions of cellular components with each other (re-
viewed in references 6, 12, and 35). In FRET, a fluorophore
(donor) in an excited state may transfer its excitation energy to
a neighboring chromophore (acceptor) nonradiatively through
dipole-dipole interactions. The efficiency of this process varies
as the inverse of the sixth power of the distance separating the
donor and acceptor chromophores and, in practice, requires
the distance between the donor and acceptor fluorophores to
be short (usually less than 50 Å). The dependence of the
energy transfer efficiency on the donor-acceptor separation
provides the basis for the utility of this phenomenon in the
study of cell component interactions. FRET has been used by
a number of investigators to examine interactions of cellular
FIG. 2. Beclin mRNA and protein expression. (A) Northern blot analysis of beclin mRNA expression in human and mouse tissues. sm., small; m., muscle. (B)
Immunoperoxidase staining of an adult human hippocampus section with a polyclonal antibody against a human Beclin peptide. The arrow marks a Beclin-positive
neuron. Magnification, 3450.
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constituents (reviewed in 6, 12, and 35) such as endosomal
fusion events, ligand-dependent growth factor receptor aggre-
gations, interactions of viral and cellular proteins with regula-
tors of apoptosis (20), and interactions of cellular cytoskeletal
components (33).
Prior to measuring FRET, we first confirmed the colocaliza-
tion of full-length Bcl-2 and Beclin in transfected COS7 cells,
using confocal laser microscopy (Fig. 4). Bcl-2 is known to
associate with the outer mitochondrial membrane, endoplas-
mic reticulum, and perinuclear membranes, and it displays a
punctate pattern of cytoplasmic immunoreactivity (reviewed in
reference 28). We found that flag-Beclin invariably displayed a
pattern of immunoreactivity identical to that of Bcl-2 in all
cotransfected COS7 cells examined by confocal laser micro-
scopic analysis (Fig. 4A to C). Furthermore, we found that
deletion of the putative Bcl-2-binding domain from Beclin did
not alter its pattern of immunoreactivity; flag-BeclinDBcl-2BD
appeared to have a pattern of staining similar to that of full-
length Beclin, and like full-length Beclin, it colocalized with
Bcl-2 in cotransfected cells (Fig. 4D to F). This granular pat-
tern of Beclin immunoreactivity in the perinuclear region is
similar to that observed for endogenous Beclin in human neu-
rons (compare Fig. 2B, 4A, and 4D).
After confirming the colocalization of Bcl-2 and Beclin and
of Bcl-2 and BeclinDBcl-2BD, we used FRET analysis to de-
termine whether Bcl-2 and Beclin physically interact. We com-
pared in transfected COS7 cells the amounts of FRET between
Bcl-2 and full-length Beclin, Bcl-2 and BeclinDBcl-2BD, and
Bcl-2 and a control protein, SERCA. Quantitative analysis of
microscopic images (following corrections for cross-talk be-
tween filter sets and donor and acceptor concentrations) showed
significantly more FRET in cells with labeled full-length Beclin
and Bcl-2 (EBeclin-Bcl-2 5 0.000578 6 0.000262; mean 6 stan-
dard error of the mean [SEM], n 5 410) than in cells with
labeled BeclinDBcl-2BD and Bcl-2 (EBeclinDBcl-2BD-Bcl-2 5
0.000189 6 0.000151; n 5 2,946) (P 5 0.0068, t test) or in cells
with labeled SERCA and Bcl-2 (ESERCA-Bcl-2 5 0.0000639 6
0.0000390; n 5 775) (P 5 0.0021, t test). These quantitative
analyses indicate that Beclin and Bcl-2 exhibit FRET and pro-
vide evidence of an interaction between these two proteins in
mammalian cells. Furthermore, deletion of the Bcl-2-binding
domain of Beclin mapped in yeast two-hybrid studies does not
alter the spatial orientation of transfected Beclin, but it does
significantly decrease FRET. This observation suggests that
the FRET observed between full-length Beclin and Bcl-2 re-
flects a specific association of these proteins in vivo, rather
than an artifact secondary to overexpression.
Selective interaction of Beclin with death repressor mem-
bers of the Bcl-2 family. To investigate whether Beclin inter-
acts with other Bcl-2 family members that positively or nega-
tively regulate apoptosis, we fused bax, bcl-xS, and bcl-xL into
the GAL4 binding domain vector and tested for interactions
with Beclin in the yeast two-hybrid system (Table 1). The
Bcl-xS GAL4 binding domain construct activated transcription
by itself and therefore could not be tested for interactions with
Beclin. The same region of Beclin (aa 88 to 150) that inter-
acted with Bcl-2 also interacted with Bcl-xL, a related Bcl-2
family member that inhibits apoptosis (4). In contrast, Beclin
did not react with Bax, a family member that promotes apo-
ptosis (27). This pattern of interaction, i.e., with Bcl-2 and
Bcl-xL, but not Bax, is identical to that observed for all previ-
ously identified Bcl-2-interacting proteins outside the Bcl-2
family (reviewed in reference 30).
Mutations in Bcl-2 and Bcl-xL that block death repressor
activity also block binding to Beclin. Cheng et al. have shown
that Bcl-2 and Bcl-xL overexpression can delay Sindbis virus-
induced death of BHK cells (5). To evaluate whether Bcl-2–
Beclin and Bcl-xL–Beclin interactions may be related to this
ability of Bcl-2 and Bcl-xL to inhibit Sindbis virus-induced
apoptosis, we constructed pGBT9 vectors containing bcl-2 and
bcl-xL constructs with mutations in the conserved BH1 domain
that are known to block death repressor activity. A Gly-Ala
mutation at amino acid position 145 of Bcl-2 completely abro-
gates Bcl-2 death repressor activity in interleukin-3 depriva-
tion-, g-irradiation- and glucocorticoid-induced apoptosis (42)
and also blocks Bcl-2 binding to Beclin in the yeast two-hybrid
system (Table 2). Similarly, substitution of aa 136 to 138 of
Bcl-xL (VNX3AIL) completely abolishes death repressor ac-
tivity in Sindbis virus-induced apoptosis (5) and also blocks
Bcl-xL binding to Beclin (Table 2). These mutations in Bcl-2
FIG. 3. Expression of flag-Beclin protein constructs by the virus vectors SIN/beclin, SIN/beclinstop, and SIN/beclinDBcl-2BD. (A and B) Western blot analyses of
virus-infected BHK cell lysates with either anti-flag epitope antibody M2 (A) or polyclonal rabbit anti-Beclin antiserum (B). Lane 1, SIN/beclin; lane 2, SIN/beclinstop;
lane 3, SIN/beclinDBcl-2BD; lane 4, empty Sindbis virus vector. (C to E) Immunoperoxidase staining using anti-flag epitope antibody M2 of mouse brains 2 days after
infection with SIN/beclin (C), SIN/beclinstop (D), or SIN/beclinDBcl-2BD (E). Magnification, 3111.
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(G3A145) and Bcl-xL (VNW3AIL) did not alter the level of
Bcl-2 or Bcl-xL expression in yeast cells (data not shown),
indicating that the lack of interaction could not be attributed to
effects of the mutations on protein expression in yeast. These
data therefore demonstrate that mutations that block the an-
tideath activity of Bcl-2 and Bcl-xL also block binding to Beclin.
Beclin protects mice against fatal encephalitis caused by the
neurovirulent TE12 strain of Sindbis virus. After identifying
Beclin as a novel Bcl-2-interacting protein that is expressed in
neurons, we were interested in studying its effects on Sindbis
virus infection. To directly evaluate the role of Beclin and its po-
tential interactions with Bcl-2-like proteins in modulating Sindbis
virus pathogenesis, we compared the natural histories of mice
infected with recombinant chimeric viruses that express either
wild-type human Beclin (SIN/beclin), human Beclin lacking the
putative Bcl-2-binding domain (SIN/beclinDBcl-2BD), or hu-
man Beclin containing a premature stop codon at nucleotide
position 270 (SIN/beclinstop).
To construct these viruses, we used a strategy identical to
that previously described for Sindbis virus chimeras that ex-
press human Bcl-2 (17), with the exception that we used a more
neurovirulent background strain of Sindbis virus, dsTE12. We
chose dsTE12 rather than the previously used less virulent
strain ds633 because of the possibility that the larger size of the
human beclin open reading frame insert would have an atten-
uating effect on Sindbis virus neurovirulence. Whereas ds633 is
neurovirulent only in neonatal mice, dsTE12 is also neuroviru-
lent in older mice (40). ds633 and dsTE12 differ at one amino
acid position in the E2 envelope glycoprotein (Gln-55 in ds633;
His-55 in dsTE12) and two amino acid positions in the E1
glycoprotein (Val-72 and Gly-313 in ds633; Ala-72 and Asp-
313 in dsTE12). Previous studies with recombinant viruses
have mapped the amino acid residue responsible for neuro-
virulence in older mice to position 55 in E2 (40, 41).
We confirmed that SIN/beclin and SIN/beclinDBcl-2BD ex-
pressed proteins of the predicted molecular weights by per-
forming Western blot analyses of infected BHK cell lysates
with both an anti-flag epitope monoclonal antibody and a poly-
clonal anti-human Beclin peptide antibody (Fig. 3A and B).
SIN/beclin expressed a 61-kDa protein and SIN/beclinDBcl-
2BD expressed a 52-kDa protein reactive with both anti-flag
FIG. 4. Confocal laser scanning microscopy of COS7 cells expressing Bcl-2 and Beclin. (A and B) Cell cotransfected with pSG5/bcl-2 and pSG5/flag-beclin and
stained with anti-flag epitope (A) and anti-human Bcl-2 (B) antibodies. (D and E) Cell cotransfected with pSG5/bcl-2 and pSG5/flag-beclinDBcl-2BD and stained with
anti-flag epitope (D) and anti-human Bcl-2 (E) antibodies. (C and F) Computerized overlays of panels A and B (C) and panels D and E (F); yellow color corresponds
to overlap of FITC and rhodamine staining. Confocal slides were 1 mm thick.
TABLE 2. Effect of BH1 domain mutations on the ability of Bcl-2
and Bcl-xL to bind to Beclin in the yeast two-hybrid assay






WT Bcl-2 ELFRDGVNWGRIVAFFEFGG 1 1
WT Bcl-xL ELFRDGVNWGRIVAFFSFGG 1 1
MT Bcl-2 ---------A---------- 2 (42) 2
MT Bcl-xL ------AIL----------- 2 (5) 2
a WT, wild-type; MT, mutant.
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epitope and anti-Beclin antibodies. We also confirmed that
human flag-Beclin and flag-BeclinDBcl-2BD were expressed in
virally infected neurons by performing immunoperoxidase stain-
ing of mouse brains at days 1, 2, and 4 after infection (repre-
sentative photomicrographs shown in Fig. 3C and E). Al-
though we did not detect any flag-Beclin protein expression by
Western blot analysis of BHK cell lysates infected with SIN/
beclinstop, flag immunoreactivity was also observed in mouse
brains infected with SIN/beclinstop (Fig. 3D). No flag immu-
noreactivity was seen in control mouse brains infected with the
dsTE12 vector alone (data not shown). Fewer flag-immunore-
active cells were observed in SIN/beclin-infected than in SIN/
beclinDBcl-2- and SIN/beclinstop-infected mouse brains.
We compared the survival of 10-day-old litters of CD1 mice
infected intracerebrally with 1,000 PFU of SIN/beclin, SIN/
beclinDBcl-2BD, and SIN/beclinstop (Fig. 5A). The survival of
mice infected with SIN/beclin was 71%, compared with only 9
and 7% after infection with SIN/beclinDBcl-2BD and SIN/
beclinstop. The differences in survival between groups infected
with SIN/beclin versus SIN/beclinDBcl-2BD and SIN/beclin ver-
sus SIN/beclinstop were highly significant (P , 0.001; life-table
analysis). Thus, full-length Beclin overexpression in virally in-
fected neural cells results in marked protection against fatal
Sindbis virus encephalitis. Furthermore, the high mortality af-
ter infection with a virus expressing a mutant form of Beclin
lacking the Bcl-2-binding domain suggests that binding to Bcl-2
or Bcl-2-like proteins is important for the protective effects of
Beclin on survival in Sindbis virus encephalitis.
Bcl-2 does not protect against fatal encephalitis caused by
TE12. Previously, we showed that Bcl-2, expressed in the ds633
Sindbis virus vector, protected neonatal mice against fatal Sind-
bis virus infection (17). However, in in vitro studies in AT3/
bcl-2 cells, the TE12 strain overcomes protection conferred by
Bcl-2 (41). To directly compare the abilities of Beclin and Bcl-2
to protect against encephalitis by TE12 in 10-day-old mice, we
cloned human bcl-2 and human bcl-2 containing a premature
stop codon after nucleotide position 118 into the dsTE12 vec-
tor to generate the constructs SIN/bcl-2 and SIN/bcl-2stop.
Unlike SIN/beclin versus SIN/beclinstop (Fig. 5A), there was
no difference in the survival of mice infected with SIN/bcl-2
versus SIN/bcl-2stop (Fig. 5B). Together with previous results
(17), these data demonstrate that Bcl-2 can protect against
fatal encephalitis caused by a strain of Sindbis virus containing
a wild-type glutamine at position E2 position 55 but not by a
more neurovirulent strain of Sindbis virus containing a histi-
dine mutation at E2 position 55 (E2-55 histidine mutation).
Beclin reduces Sindbis virus replication in mouse brain. To
examine whether Beclin overexpression affects Sindbis virus
replication, we measured viral titers of mouse brain homoge-
nates and performed in situ hybridization of mouse brain sec-
tions to detect message-sense viral RNA. Mean viral titers were
reduced 5-fold at day 1 and 50-fold at days 2 and 4 after in-
fection in brains of mice infected with SIN/beclin compared to
the brains of mice infected with SIN/beclinstop or SIN/beclinDbcl-
2BD (Fig. 6). Computerized quantitative image analysis of vi-
rus RNA positive cells in infected mouse brains showed an
inhibitory effect of Beclin on viral replication that was similar
to, but had a temporal pattern somewhat different from, that
observed by measurement of viral titers (Fig. 7). The mean
number of virus RNA-positive cells was significantly lower in
brains infected with SIN/beclin than in brains infected with
SIN/beclinstop at day 4 after infection (100 6 36 versus 494 6
55; P 5 0.004, t test) but was equivalent at day 2 after infection
(575 6 272 versus 507 6 216; P 5 0.854, t test). The reduction
of viral titers but not of virus RNA-positive cells in mouse
FIG. 5. Effects of Beclin and Bcl-2 on the survival of mice infected with Sindbis virus strain TE12. (A) Survival curve of mice infected with SIN/beclin, SIN/beclinstop,
and SIN/beclinDBcl-2BD. Data represent combined survival probabilities for four to six independent litters. (B) Survival curve of mice infected with SIN/bcl-2 and SIN/
bcl-2stop. Data represent combined survival probabilities for three independent litters.
FIG. 6. Viral growth of SIN/beclin, SIN/beclinstop, and SIN/beclinDBcl-2BD
in mouse brain. Each data point represents geometric mean viral titer 6 SEM of
three to six mouse brains.
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brains 2 days after infection with SIN/beclin suggests a possible
inhibitory effect of Beclin on posttranscriptional stages of viral
replication. In addition, the viral titers of SIN/beclinDBcl-2BD-
infected mouse brains did not differ significantly from titers
of SIN/beclinstop-infected mouse brains, but the number of
virus RNA-positive cells was higher at days 2 and 4 in SIN/
beclinDBcl-2BD-infected than in SIN/beclinstop-infected
mouse brains. This difference was significant at day 4 (905 6 72
versus 494 6 55; P 5 0.01, t test) but not at day 2 (1,190 6 375
versus 507 6 216; P 5 0.190, t test) after infection.
The anatomic distribution of RNA-positive cells did not
differ among the different virus-infected groups; viral RNA-
positive cells were found in clusters scattered throughout the
brain, most commonly in the subventricular zone, posterior neo-
cortex, colliculus, hippocampus, striatum, and olfactory bulb.
However, the number of cells seen within a given cluster was
usually lowest in SIN/beclin-infected mouse brains and greatest
in SIN/beclinDBcl-2BD-infected mouse brains (see represen-
tative photomicrographs in Fig. 9).
Beclin reduces Sindbis virus-induced cell death in mouse
brain. To examine whether CNS Beclin overexpression re-
duces apoptotic cell death, we quantitated the number of ap-
optotic nuclei in the brains of mice infected with the chimeric
viruses SIN/beclin, SIN/beclinstop, and SIN/beclinDBcl-2BD
(Fig. 8). Within each mouse brain, almost all apoptotic nuclei
were found in regions that had detectable viral RNA by in situ
hybridization (Fig. 9) and in regions that had histopathologic
evidence of neuronal death. A close association was observed
between the mean numbers of apoptotic nuclei at each time
point among the three different virus treatment groups and the
mean numbers of virus RNA-positive cells (compare results in
Fig. 7 and 8). In mouse brains infected with SIN/beclin and
SIN/beclinstop, little cell death was seen at days 1 and 2 after
infection, and the number of apoptotic cells per square milli-
meter of brain did not differ between these groups. More
apoptotic nuclei were present at day 2 after infection in the
brains of mice infected with SIN/beclinDBcl-2BD (604 6 211)
than in the brains of mice infected with SIN/beclin (133 6 90)
or SIN/beclinstop (91 6 52); this difference was nearly statis-
tically significant (P 5 0.078, analysis of variance). At day 4
after infection, the mean number of apoptotic cells per square
millimeter of brain was markedly increased in SIN/beclinstop
(1,490 6 29) and SIN/beclinDBcl-2BD (1,044 6 430) versus
SIN/beclin-infected mouse brains (101 6 10; P 5 0.001, anal-
ysis of variance). These data demonstrate that Beclin overex-
pression decreases apoptotic death in mouse brains infected
with the TE12 strain of Sindbis virus.
DISCUSSION
In this study, we describe the identification of a novel coiled-
coil 60-kDa protein, Beclin, which interacts with the cell death
regulator Bcl-2. We demonstrate that Beclin overexpression in
virally infected neurons in vivo results in substantial protection
against Sindbis virus-induced disease. Mice infected with re-
combinant Sindbis viruses that express wild-type Beclin have
less neural cell apoptosis, decreased viral replication, and a
significant lower mortality rate than mice infected with recom-
binant viruses that express Beclin deletion mutants. Further-
more, the Bcl-2-binding domain of Beclin is required for the
antiviral, antiapoptotic, and survival-promoting effects of Bec-
lin on CNS Sindbis virus infection. These findings suggest that
Beclin, via interactions with Bcl-2-like molecules, can function
in vivo in the CNS as an antiviral host defense molecule.
Our conclusion that the protective, antiviral effects of Beclin
are mediated through interactions with Bcl-2 (or Bcl-2-like
molecules that bind to same region of Beclin as Bcl-2) is sup-
ported by data obtained with a chimeric Sindbis virus express-
ing Beclin lacking aa 88 to 151. Amino acids 88 to 150 of Beclin
are sufficient to mediate an interaction with Bcl-2 and Bcl-xL in
the yeast two-hybrid assay, and deletion of these amino acids
from full-length Beclin significantly decreases the strength of
the Beclin-Bcl-2 interaction in mammalian cells. The Sindbis
virus construct expressing Beclin lacking aa 88 to 150 (SIN/
beclinDBcl-2BD) replicated to as high levels in mouse brain,
resulted in as much apoptotic neural cell death, and resulted in
the same mortality in mice as a control recombinant virus
which expressed a 90-aa truncated Beclin protein (SIN/beclin-
stop). The lack of protective activity of BeclinDBcl-2BD com-
pared to full-length Beclin cannot be attributed to lower lev-
els of BeclinDBcl-2BD expression after infection with SIN/
beclinDBcl-2BD. The levels of flag-BeclinDBcl-2BD were
equal to or greater than levels of flag-Beclin detected by im-
munoblot analysis of lysates from BHK cells infected with SIN/
beclin and SIN/beclinDBcl-2BD, respectively. In addition, SIN/
beclinDBcl-2BD-infected mouse brains had more flag-immu-
noreactive cells than mouse brains infected with SIN/beclin.
FIG. 7. Viral RNA-positive cells in mouse brains infected with SIN/beclin,
SIN/beclinstop, and SIN/beclinDBcl-2BD. Each data point represents the
mean 6 SEM number of Sindbis virus message-sense RNA-positive cells per
square millimeter of brain for three to six mouse brains.
FIG. 8. Apoptotic nuclei in mouse brains infected with SIN/beclin, SIN/bec-
linstop, and SIN/beclinDBcl-2BD. Each data point represents the mean 6 SEM
number of ISEL-positive nuclei per square millimeter of brain for three to six
mouse brains.
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Thus, the lack of protective activity of BeclinDBcl-2 is most
consistent with the hypothesis that the antiviral effects of Bec-
lin are mediated through interactions with Bcl-2-like proteins.
Some of the data in the present study suggest that the virus
SIN/beclinDBcl-2BD may be more neurovirulent than the virus
SIN/beclinstop. Mice infected with SIN/beclinDBcl-2BD had
more virus RNA-positive cells in their brains at days 2 and 4
after infection than mice infected with SIN/beclinstop. Corre-
sponding to the more rapid spread of infection, more cell death
was seen earlier on after infection in the brains of mice in-
fected with SIN/beclinDBcl-2BD compared to SIN/beclinstop.
Although the overall mortality rates of mice infected with SIN/
beclinDBcl-2BD versus SIN/beclin stop did not differ, but the
mean day of death was slightly lower in mice infected with SIN/
beclinDBcl-2BD versus SIN/beclinstop. These observations
raise the possibility that Beclin lacking the Bcl-2-binding do-
main functions as a dominant negative mutant. As a corollary,
the naturally occurring Beclin isoform found in brain that lacks
the Bcl-2-binding domain may serve as a death-promoting mol-
ecule.
Beclin may exert antiviral effects via interactions with either
Bcl-2, Bcl-xL, or yet unidentified Bcl-2 family members. In
yeast two-hybrid assays, we found that the same region of
Beclin interacted with Bcl-2 and Bcl-xL and that loss-of-func-
tion mutations in the conserved BH1 domains of both Bcl-2
and Bcl-xL blocked binding to Beclin. While both Bcl-2 and
Bcl-xL are important regulators of apoptosis in neurons (re-
viewed in reference 23), we have found that Bcl-2, but not
Bcl-xL, protects mice against fatal encephalitis and delays Sind-
bis virus-induced death of cultured rat dorsal root ganglion
neurons (14, 17). Thus, Bcl-2 may be more important than
Bcl-xL as a regulator of Sindbis virus-induced death in neural
cells. Additional studies examining the effects of Beclin on
Sindbis virus infection in mice that are deficient in Bcl-2 may
help define whether Bcl-2 is the biologically important Beclin-
binding partner in in vivo antiviral pathways in the CNS.
The mechanisms by which Beclin, in cooperation with Bcl-
2-like proteins, functions to inhibit Sindbis virus replication
and Sindbis virus-induced neuronal death are unknown. Both
Semliki Forest virus and Sindbis virus have been shown to
inactivate the antiapoptotic function of Bcl-2 in transfected
fibroblasts through caspase-induced Bcl-2 cleavage (10). In
addition, Nava et al. have shown that crmA increases the sur-
vival of Sindbis virus-infected mice (24), suggesting a role for
crmA-inhibitable CNS caspase activity in the pathogenesis of
fatal encephalitis. One possibility, therefore, is that binding to
Beclin somehow protects Bcl-2 (or Bcl-xL) from cleavage by
caspases, thereby preventing Sindbis virus-induced cell death.
A second possibility is that the Beclin–Bcl-2-like protein com-
plex blocks an endoplasmic reticulum stress signal triggered by
the Sindbis virus E2 and E1 envelope glycoproteins. One of the
mechanisms by which Bcl-2 and Bcl-may inhibit apoptosis is by
regulating the permeability of intracellular membranes (re-
viewed in reference 30). Recently, we have shown that the
overexpression of the transmembrane domains of the Sind-
bis virus E2 and E1 envelope glycoproteins induces apoptosis
in AT3 cells (15). In addition, coiled-coil proteins such as
Beclin may play a role in linking membrane signal transduction
events with the cytoskeleton. Thus, we speculate that Beclin, a
protein which localizes to intracellular membranes, may be
part of a complex with Bcl-2-like proteins that regulates sig-
nalling events initiated by Sindbis virus envelope glycoproteins
in the endoplasmic reticulum.
Many similarities exist between the findings of the present
study and our previous work examining the effects of Bcl-2
overexpression on the natural history of Sindbis virus enceph-
alitis. As observed with Beclin in this study, the overexpression
of Bcl-2 in virally infected neurons has previously been shown
to reduce CNS apoptosis, reduce CNS Sindbis virus replica-
tion, and reduce Sindbis virus mortality (17). However, in the
present study, we also identify one significant biologic differ-
ence between Bcl-2 and Beclin; namely, Beclin can exert pro-
FIG. 9. Representative photomicrographs of fields used for computerized quantitative image analysis of viral RNA (A to C)- and ISEL (D to F)-positive cells in
mouse brains infected with SIN/beclin (A and D), SIN/beclinstop (B and E), and SIN/beclinDBcl-2BD (C and F) in Fig. 7 and 8, respectively. All photomicrographs
are from the colliculus region of brain sections 4 days after infection and correspond to the images observed at a magnification of 310. Arrowheads denote
representative cells that were scored as positive by the Image-ProPlus software program.
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tective effects against infection by a neurovirulent strain of
Sindbis virus that is known to overcome the protective effects
of Bcl-2. Ubol et al. demonstrated that a histidine substitution
for wild-type glutamine at position 55 of the Sindbis virus E2
envelope glycoprotein was sufficient to enable the virus to kill
cells expressing Bcl-2 (41). Similarly, we have previously found
that Bcl-2 expressed in a strain of Sindbis containing a glu-
tamine at position 55 (strain 633) protects against fatal enceph-
alitis (17), but in the present study, we found that Bcl-2 ex-
pressed in a strain of Sindbis containing a histidine at position
55 (strain TE12) confers no protection against fatal disease.
Yet, when expressed in an E2-55 histidine-containing back-
ground strain of Sindbis virus, Beclin confers significant pro-
tection. Thus, the mutation in E2, which confers neuroviru-
lence, can counter the protective effects of Bcl-2 but not of
Beclin.
Several explanations have been proposed to explain the abil-
ity of the E2-55 histidine mutation to confer resistance to Bcl-2
protection against Sindbis virus-induced death. Ubol et al.
suggested that the neurovirulent mutation in E2 might some-
how alter either a direct interaction between E2 and Bcl-2 in
the endoplasmic reticulum or a possible effect of Bcl-2 on E2
protein folding or posttranslational modifications (41). More
recently, Grandgirard et al. raised the possibility that the mu-
tation in E2 facilitates the access of caspases to Bcl-2 and
subsequent triggering of Bcl-2 cleavage (10). If viral activation
of caspase-induced cleavage of Bcl-2 does prove to be an im-
portant mechanism of neurovirulence of Sindbis virus strains
containing E2-55 histidine, our data suggest that Beclin may
serve as an important host defense factor against this strategy
of neurovirulence. This hypothesis is based on the ability of
Beclin, a Bcl-2-interacting protein, to protect against neuronal
death induced by the TE12 strain of Sindbis virus.
Our findings suggest that the antiviral effects of Beclin ob-
served in Sindbis virus-infected mouse brains may be exerted at
a stage of viral replication after viral RNA synthesis. At 2 days
after chimeric virus infection, Beclin overexpression was asso-
ciated with a 50-fold reduction in viral titers but no reduction
in the number of viral RNA-positive cells. This finding suggests
a block or abnormality at the level of either translation of the
Sindbis virus structural proteins, posttranslational modifica-
tions of viral glycoproteins, virus assembly, or budding. This
observation contrasts with previous studies examining the ef-
fects of Bcl-2 on infection with a related alphavirus, Semliki
Forest virus (34). On the basis of in situ hybridization studies
for viral RNA and immunostaining for viral proteins, Scallan et
al. concluded that bcl-2 functions at an early stage of the virus
life cycle, either entry, pretranscriptional events, or tran-
scription, to inhibit Semliki Forest virus replication (34).
The discrepancy between the findings of Scallan et al. and
those reported in the present study may reflect fundamental
differences between the antiviral effects of Beclin and Bcl-2,
differences between Sindbis virus and Semliki Forest virus, or
differences between the cell types infected. Alternatively, it is
possible that Bcl-2 and/or Beclin act at multiple overlapping
stages of the alphavirus life cycle and that different experimen-
tal designs in the two studies uncovered effects on different
phases of replication. Given the lack of antiviral activity of
Beclin lacking the Bcl-2-binding domain, it seems likely that
the mechanisms by which Beclin and Bcl-2 inhibit Sindbis virus
replication in mouse brain are similar.
The results of the present study do not permit us to evaluate
whether the beneficial effects of Beclin on Sindbis virus-in-
duced mortality are a consequence of antiviral effects, anti-
apoptotic effects, or a combination of both. It is not known
whether Beclin prevents neural cell death solely as a conse-
quence of reducing Sindbis virus replication in neurons or
whether Beclin exerts antiapoptotic effects independently of its
effects on viral replication. Further studies examining the ef-
fects of Beclin on apoptotic death in response to nonviral
stimuli will be necessary to determine whether Beclin, like Bcl-
2, functions as a general apoptosis inhibitor. If so, structure-
function analyses of Beclin may be helpful to map domains
important for antiviral and antiapoptotic function and to iden-
tify whether these two properties are interrelated or indepen-
dent.
Previously, based on our observations with Bcl-2 and Sindbis
virus infection, we postulated that molecular links may exist
between cellular regulation of viral replication and cellular
regulation of apoptotic death in neurons (17). Our findings
that Beclin has antiviral activity and that Beclin interacts with
the cell death regulator Bcl-2 further support this hypothesis.
In dividing cells, inhibition of virus-induced cell death by virally
encoded cell death inhibitors such as p35 (7) and adenovirus
E1B can increase viral replication (3). However, in nondivid-
ing, terminally differentiated cells such as neurons, genetic
pathways may exist which permit preservation of the life of the
cell, without the adverse consequence of increased total viral
burden for the organism. Genes such as bcl-2 and beclin that
are normally expressed in mammalian neurons may be impor-
tant components of such pathways.
ACKNOWLEDGMENTS
The first two authors contributed equally to this work.
We thank M. B. Soares for providing the normalized human infant
brain cDNA library, Takaki Sato for providing bcl-xS, bcl-xL, and bax
plasmids, Steven Greenberg and Milton Packer for helpful discussions,
and Tracey Curran for secretarial assistance.
This work was supported by a James S. McDonnell Foundation
Scholar Award (B.L.) and NIH grants AIO1217 (B.L.), AI40246
(B.L.), AG07218 (B.H.), AG13797 (B.H.), and AG13637 (B.H.). B.L.
was supported by an American Cancer Society Junior Faculty Re-
search Award and an Irma T. Hirschl Trust Career Scientist Award.
REFERENCES
1. Allsopp, T. E., M. F. Scallan, A. Williams, and J. K. Fazakerley. 1998. Virus
infection induces neuronal apoptosis: a comparison with trophic factor with-
drawal. Cell Death Differ. 5:50–59.
2. Altshul, S. F., W. Gish, W. Miller, E. W. Meyers, and D. J. Lipman. 1990.
Basic local alignment tool. J. Mol. Biol. 215:403–410.
3. Antoni, B. A., P. A. Sabbatini, A. B. Rabson, and E. White. 1995. Inhibition
of apoptosis in human immunodeficiency virus-infected cells enhances virus
production and facilitates persistent infection. J. Virol. 69:2384–2392.
4. Boise, L. H., M. Gonzalez-Garcia, C. E. Postema, L. Ding, T. Lindsten, L. A.
Turka, X. Mao, G. Nunez, and C. B. Thompson. 1993. Bcl-xL, a bcl-2 related
gene that functions as a dominant regulator of apoptotic cell death. Cell
74:597–608.
5. Cheng, E. H. Y., B. Levine, L. H. Boise, C. B. Thompson, and J. M. Hard-
wick. 1996. Bax-independent inhibition of apoptosis by Bcl-xL. Nature 379:
554–556.
6. Clegg, R. M. 1992. Fluorescence resonance energy transfer and nucleic acids.
Methods Enzymol. 211:353–388.
7. Clem, R., and L. K. Miller. 1993. Apoptosis reduces both the in vitro
replication and the in vivo infectivity of baculovirus. J. Virol. 67:3730–3738.
8. Friedman, L. S., E. A. Ostermeyer, E. D. Lynch, C. I. Szabo, L. A. Anderson,
P. Dowd, M. K. Lee, S. E. Rowell, J. M. Boyd and M.-C. King. 1994. The
search for BRCA1. Cancer Res. 54:6374–6382.
9. Gordon, G. W., G.-Berry, X. H. Liang, B. Levine, and B. Herman. 1998.
Quantitative fluorescence resonance energy transfer (FRET) measurements
using fluorescence microscopy. Biophys. J. 74:2702–2713.
10. Grandgirard, D., E. Studer, L. Monney, T. Belser, I. Fellay, C. Borner, and
M. R. Michel. 1998. Alphaviruses induce apoptosis in Bcl-2-overexpressing
cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2.
EMBO J. 17:1268–1278.
11. Hardwick, J. M. 1997. Virus-induced apoptosis. Adv. Pharmacol. 41:295–
336.
12. Herman, B. 1996. Fluorescence microscopy: state of the art, p. 1–14. In J.
Slavik (ed.), Fluorescent microscopy and fluorescent probes. Plenum Press,
New York, N.Y.
VOL. 72, 1998 PROTECTION AGAINST SINDBIS VIRUS INFECTION BY BECLIN 8595
13. Hinshaw, V. S., C. W. Olsen, N. Dybdahl-Sissoko, and D. Evans. 1994.
Apoptosis: a mechanism of cell killing by influenza A and B viruses. J. Virol.
68:3667–3673.
14. Jiang, H. H., and B. Levine. Unpublished data.
15. Joe, A. K. H. H. Foo, L. Kleeman, and B. Levine. 1998. The transmembrane
domains of Sindbis virus envelope glycoproteins induce cell death. J. Virol.
72:3935–3943.
16. Krakauer, D. C., and R. J. Payne. 1997. The evolution of virus-induced
apoptosis. Proc. R. Soc. Lond. Ser. B 264:1757–1762.
17. Levine, B., J. E. Goldman, H. H. Jiang, D. E. Griffin, and J. M. Hardwick.
1996. Bcl-2 protects mice against fatal alphavirus encephalitis. Proc. Natl.
Acad. Sci. USA 93:4810–4815.
18. Levine, B., Q. Huang, J. T. Isaacs, J. C. Reed, D. E. Griffin, and J. M.
Hardwick. 1993. Conversion of lytic to persistent alphavirus infection by the
bcl-2 cellular oncogene. Nature 361:739–742.
19. Lewis, J., S. L. Wesslingh, D. E. Griffin, and J. M. Hardwick. 1996. Alpha-
virus-induced apoptosis in mouse brains correlates with neurovirulence.
J. Virol. 70:1828–1835.
20. Liang, X. H., M. Volkmann, R. Klein, B. Herman, and B. Lockett. 1994.
Colocalization of tumor suppressor protein p53 and human papillomavirus
E6 protein in human cervical carcinoma cell lines. Oncogene 8:2645–2652.
21. Liao, C. L., Y. L. Lin, J. J. Wang, Y. L. Huang, C. T. Yeh, S. H. Ma, and L. K.
Chen. 1997. Effect of enforced expression of human bcl-2 on Japanese
encephalitis virus-induced apoptosis in cultured cells. J. Virol. 71:5963–5971.
22. Lupas, A., M. Van Dyke, and M. J. Stock. 1991. Predicting coiled coils from
protein sequences. Science 252:1162–1164.
23. Merry, D. E., and S. J. Korsmeyer. 1997. Bcl-2 gene family in the nervous
system. Annu. Rev. Neurosci. 20:245–267.
24. Nava, V. E., A. Rosen, M. A. Veliuona, R. J. Clem, B. Levine, and J. M.
Hardwick. 1998. Sindbis virus induces apoptosis through a caspase-depen-
dent CrmA-sensitive pathway. J. Virol. 72:452–459.
25. Oberhaus, S. M., R. L. Smith, G. W. Clayton, T. S. Dermody, and K. L. Tyler.
1997. Reovirus infection and tissue injury in the mouse central nervous
system are associated with apoptosis. J. Virol. 71:2100–2106.
26. Olsen, C. W., J. C. Kehren, N. R. Dybdahl-Sissoki, and V. S. Hinshaw. 1996.
bcl-2 alters influenza virus, yield, spread, and hemagglutinin glycosylation.
J. Virol. 80:663–666.
27. Oltvai, Z., C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 heterodimerizes
in vivo with a conserved homolog, Bax, that accelerates programmed cell
death. Cell 74:609–619.
28. Park, J. R., and D. M. Hockenbery. 1996. Bcl-2, a novel regulator of apo-
ptosis. J. Cell. Biochem. 60:12–17.
29. Pekosz, A., J. Phillips, D. Pleasure, D. Merry, and F. Gonzalez-Scarano.
1996. Induction of apoptosis by LaCrosse virus infection and role of neuronal
differentiation and human bcl-2 expression in its prevention. J. Virol. 70:
5329–5335.
30. Reed, J. C. 1997. Double identity for proteins of the Bcl-2 family. Nature.
387:773–776.
31. Rodgers, S. E., E. S. Barton, S. M. Oberhaus, B. Pike, C. A. G. Terence, K. L.
Tyler, and T. S. Dermody. 1997. Reovirus-induced apoptosis of MDCK cells
is not linked to viral yield and is blocked by Bcl-2. J. Virol. 71:2540–2546.
32. Rommens, J. M., F. Durocher, J. McArthur, P. Tonin, J.-F. LeBlanc, T.
Allen, C. Samson, L. Ferri, S. Narod, K. Morgan, and J. Simard. 1995.
Generation of a transcription map at the HSD17B locus centromeric to
BRCA1 at 17q21. Genomics 28:530–542.
33. Root, D. D. 1997. In situ molecular association of dystrophin with actin
revealed by sensitized emission immuno-resonance energy transfer. Proc.
Natl. Acad. Sci. USA 94:5685–5690.
34. Scallan, M. F., T. E. Allsopp, and J. K. Fazakerley. 1997. bcl-2 acts early to
restrict Semliki Forest virus replication and delays virus-induced pro-
grammed cell death. J. Virol. 71:1583–1590.
35. Selvin, P. R. 1995. Fluorescence resonance energy transfer. Methods Enzy-
mol. 246:300–333.
36. Shen, Y., and T. E. Shenk. 1995. Viruses and apoptosis. Curr. Opin. Genet.
Dev. 5:105–111.
37. Soares, M. B., M. F. Bonaldo, P. Jelene, L. Su, L. Lawton, and A. Efstra-
diadis. 1994. Construction and characterization of a normalized cDNA li-
brary. Proc. Natl. Acad. Sci. USA 91:9228–9232.
38. Tangir, J., M. G. Muto, R. S. Berkowitz, W. R. Welch, D. A. Bell, and S. C.
Mok. 1996. A 400 kb novel deletion unit centromeric to the BRCA1 gene in
sporadic epithelial ovarian cancer. Oncogene 12:735–740.
39. Teodoro, J. G., and P. E. Branton. 1997. Regulation of apoptosis by viral
gene products. J. Virol. 71:1739–1746.
40. Tucker, P. C., E. G. Strauss, R. J. Kuhn, J. H. Strauss, and D. E. Griffin.
1993. Viral determinants of age-dependent virulence of Sindbis virus for
mice. J. Virol. 67:4605–4610.
41. Ubol, S., P. C. Tucker, D. E. Griffin, and J. M. Hardwick. 1994. Neuroviru-
lent strains of alphavirus induce apoptosis in bcl-2-expressing cells: role of a
single amino acid change in the E2 glycoprotein. Proc. Natl. Acad. Sci. USA
91:5202–5206.
42. Yin, X.-M., Z. N. Oltvai, and S. J. Korsmeyer. 1994. BH1 and BH2 domains
of Bcl-2 are required for inhibition of apoptosis and heterodimerization with
BAX. Nature 369:321–323.
8596 LIANG ET AL. J. VIROL.
